Research Article Details
| Article ID: | A43141 |
| PMID: | 32443199 |
| Source: | Environ Pollut |
| Title: | Lipidomics insight into chronic exposure to ambient air pollution in mice. |
| Abstract: | More recent evidences are supportive of air pollution exposure on diabetes risk, including worsening of whole-body insulin sensitivity, enhancement of hepatic lipogenesis and nonalcoholic fatty liver disease after fine particulate matter (PM2.5) exposure. Therefore, we aimed to explore the lipidomics to get a comprehensive insight about ambient real-world PM2.5 exposure on lipid metabolism in blood and liver. After ambient PM2.5 exposure for 6 months, excess triglyceride accumulation in the liver was observed. Remarkable metabolic alterations including neutral lipids, glycerophospholipids and sphingolipids were noticed. Lipidomic signatures in liver is different from plasma in response to PM2.5 exposure. Lipids including species of ceramide, sphingomyeline and triglyceride may become potential biomarkers of lipotoxicity contributing to PM2.5-induced metabolic dysfunction, and the present study may serve as a reference lipid bank for further studies. |
| DOI: | 10.1016/j.envpol.2020.114668 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D258 | Omega 3 PUFA | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Hypolipidemic drug | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D125 | Epanova | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Enhance lipid metabolism | Under clinical trials | Details |